Skip to main content
Springer Nature Link
Log in

Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via PI3K/AKT pathway

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

We aim to evaluate the diagnostic value of ribonuclease inhibitor (RI) in colorectal cancer (CRC) and investigate the important role of RI in cell growth and metastasis of CRC.

Methods/patients

In this study, the expression of RI was evaluated in human CRC samples with different histological grade and the association between RI expression and clinicopathological parameters was investigated. Furthermore, the exogenous RI gene was introduced into human HT29 CRC cells and the effects of RI on cell proliferation and metastasis were determined in vitro. The PI3K/Akt signaling pathway and some related protein molecules were detected.

Results

RI is downregulated in CRC tissues compared to adjacent normal tissues and its expression is inversely associated with histological grade, pathological stage, and venous invasion, respectively. Multivariate analysis showed that RI expression was an independent prognostic factor for overall survival. In addition, the exogenous overexpression of RI reduced the proliferation and migration of HT29 CRC cell line in vitro by inhibiting the PI3K/Akt signaling pathway and suppressing the expression of vascular endothelial growth factor (VEGF) and upregulating phosphatase and tensin homolog (PTEN).

Conclusions

RI represents an important predictor of progression in patients with CRC and suppresses proliferation and metastasis in CRC cells through inhibiting PI3K/AkT pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.

    Article  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  3. Kobe B, Deisenhofer J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature. 1995;374(6518):183–6. doi:10.1038/374183a0.

    Article  CAS  PubMed  Google Scholar 

  4. Kobe B, Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature. 1993;366(6457):751–6. doi:10.1038/366751a0.

    Article  CAS  PubMed  Google Scholar 

  5. Shapiro R. Cytoplasmic ribonuclease inhibitor. Methods Enzymol. 2001;341:611–28 (pii: S0076-6879(01)41180-3).

    Article  CAS  PubMed  Google Scholar 

  6. Futami J, Tsushima Y, Murato Y, Tada H, Sasaki J, Seno M, et al. Tissue-specific expression of pancreatic-type RNases and RNase inhibitor in humans. DNA Cell Biol. 1997;16(4):413–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nadano D, Yasuda T, Takeshita H, Uchide K, Kishi K. Purification and characterization of human brain ribonuclease inhibitor. Arch Biochem Biophys. 1994;312(2):421–8. doi:10.1006/abbi.1994.1328.

    Article  CAS  PubMed  Google Scholar 

  8. Yao X, Li D, Xiong DM, Li L, Jiang R, Chen JX. A novel role of ribonuclease inhibitor in regulation of epithelial-to-mesenchymal transition and ILK signaling pathway in bladder cancer cells. Cell Tissue Res. 2013;353(3):409–23. doi:10.1007/s00441-013-1638-2.

    Article  CAS  PubMed  Google Scholar 

  9. Pan X, Xiong D, Yao X, Xin Y, Zhang L, Chen J. Up-regulating ribonuclease inhibitor inhibited epithelial-to-mesenchymal transition and metastasis in murine melanoma cells. Int J Biochem Cell Biol. 2012;44(6):998–1008. doi:10.1016/j.biocel.2012.03.008.

    Article  CAS  PubMed  Google Scholar 

  10. Chen JX, Gao Y, Liu JW, Tian YX, Zhao J, Cui XY. Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells. Int J Biochem Cell Biol. 2005;37(6):1219–31. doi:10.1016/j.biocel.2004.11.020.

    Article  CAS  PubMed  Google Scholar 

  11. Tian YX, Wang DM, Cui XY. Analysis of gene expression of ribonuclease inhibitor in human breast cancer tissue. Ai Zheng. 2004;23(3):269–72 (pii: 10000467X2004030269).

    CAS  PubMed  Google Scholar 

  12. Fan J, Wang S, Yu S, He J, Zheng W, Zhang J. N-acetylglucosaminyltransferase IVa regulates metastatic potential of mouse hepatocarcinoma cells through glycosylation of CD147. Glycoconj J. 2012;29(5–6):323–34. doi:10.1007/s10719-012-9414-1.

    Article  CAS  PubMed  Google Scholar 

  13. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, et al. Involvement of PI3 K/PTEN/AkT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res. 2009;39(2):177–86. doi:10.1111/j.1872-034X.2008.00449.x.

    Article  CAS  PubMed  Google Scholar 

  14. Lee FS, Vallee BL. Structure and action of mammalian ribonuclease (angiogenin) inhibitor. Prog Nucleic Acid Res Mol Biol. 1993;44:1–30.

    Article  CAS  PubMed  Google Scholar 

  15. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001;11(6):725–32 (pii: S0959-440X(01)00266-4).

    Article  CAS  PubMed  Google Scholar 

  16. Xu ZP, Tsuji T, Riordan JF, Hu GF. The nuclear function of angiogenin in endothelial cells is related to rRNA production. Biochem Biophys Res Commun. 2002;294(2):287–92. doi:10.1016/S0006-291X(02)00479-5S0006-291X(02)00479-5.

    Article  CAS  PubMed  Google Scholar 

  17. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci U S A. 1994;91(5):1677–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Dickson KA, Haigis MC, Raines RT. Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol. 2005;80:349–74. doi:10.1016/S0079-6603(05)80009-1.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Dickson KA, Kang DK, Kwon YS, Kim JC, Leland PA, Kim BM, et al. Ribonuclease inhibitor regulates neovascularization by human angiogenin. Biochemistry. 2009;48(18):3804–6. doi:10.1021/bi9005094.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Fu P, Chen J, Tian Y, Watkins T, Cui X, Zhao B. Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor. Cancer Gene Ther. 2005;12(3):268–75. doi:10.1038/sj.cgt.7700742.

    Article  CAS  PubMed  Google Scholar 

  21. Zhou JH, Tang XY, Zhao R, Wang H, Xia J. Effects of ribonuclease inhibitor on apoptosis and invasion of human breast cancer MDA-MB-231 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28(3):260–4.

    PubMed  Google Scholar 

  22. Pizzo E, Sarcinelli C, Sheng J, Fusco S, Formiggini F, Netti P, et al. Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival. J Cell Sci. 2013;126(Pt 18):4308–19. doi:10.1242/jcs.134551.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Chen J, Ou-Yang X, Gao J, Zhu J, He X, Rong J. Knockdown of ribonuclease inhibitor expression with siRNA in non-invasive bladder cancer cell line BIU-87 promotes growth and metastasis potentials. Mol Cell Biochem. 2011;349(1–2):83–95. doi:10.1007/s11010-010-0663-7.

    Article  CAS  PubMed  Google Scholar 

  24. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer. 2005;104(2):427–38. doi:10.1002/cncr.21145.

    Article  CAS  PubMed  Google Scholar 

  25. Xiao N, Qi XY, Tang LN, Tan LL, Chen YQ, Zhao HM. VEGF promotes cardiac stem cells differentiation into vascular endothelial cells via the PI3 K/Akt signaling pathway. Artif Cells Nanomed Biotechnol. 2013. doi:10.3109/21691401.2013.837473.

    PubMed  Google Scholar 

  26. Xu J, Jia L, Ma H, Li Y, Ma Z, Zhao Y. Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3 K/Akt-PAK1 signal pathway. Tumour Biol. 2013;35(4):3809–17. doi:10.1007/s13277-013-1521-5.

    Article  PubMed  Google Scholar 

  27. Sussman M. “AKT”ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation. Trends Cardiovasc Med. 2007;17(7):235–40. doi:10.1016/j.tcm.2007.08.003.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3 K/AKT signaling in A549 lung cancer cells. Int J Cancer. 2010;127(5):1081–95. doi:10.1002/ijc.25134.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Achiwa Y, Hasegawa K, Udagawa Y. Regulation of the phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci Biotechnol Biochem. 2007;71(1):31–7 (pii: JSTJSTAGE/bbb/60288).

    Article  CAS  PubMed  Google Scholar 

  30. Molinari F, Frattini M. Functions and regulation of the PTEN gene in colorectal cancer. Front Oncol. 2014;3:326. doi:10.3389/fonc.2013.00326.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Grant from the National Science Foundation of China (No. 81302310 and No. 31400687).

Conflict of interest

The authors have declared that no conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Pathology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China

    Y. Tang

  2. Regenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China

    P. Liu

  3. Department of Biochemistry and Molecular Biology, Dalian Medical University, 9 South Lvshun Road Western Section, Dalian, 116044, China

    Y. Tian, Y. Xu, F. Ren, X. Cui & J. Fan

Authors
  1. Y. Tang
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. P. Liu
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Y. Tian
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Y. Xu
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. F. Ren
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. X. Cui
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. J. Fan
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to J. Fan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, Y., Liu, P., Tian, Y. et al. Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via PI3K/AKT pathway. Clin Transl Oncol 17, 306–313 (2015). https://doi.org/10.1007/s12094-014-1228-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1228-0

Keywords